• The One Lonza organizational structure became effective on 1 April 2025 and comprises three CDMO Business Platforms: Integrated Biologics, Advanced Synthesis and Specialized Modalities
• Lonza reports 2024 financials for the CDMO Business Platforms for sales, CORE EBITDA, CORE EBITDA margin and CapEx for the purpose of comparison ahead of reporting its Half-Year 2025 financial results
• The Capsules & Health Ingredients business continues to operate in its existing structure

Basel, Switzerland, 27 May 2025 – Prior to reporting its Half-Year Results 2025 on 23 July 2025, Lonza is today providing comparative financials for 2024 to reflect its One Lonza operating model, which became effective on 1 April 2025. Designed to support the One Lonza vision and strategy, the new organizational structure comprises three CDMO Business Platforms, which manage multiple technology platforms:

• Integrated Biologics comprises the Mammalian and Drug Product Services technologies, alongside the Licensing business
• Advanced Synthesis comprises the Small Molecules and Bioconjugates technologies
• Specialized Modalities includes the Cell & Gene, mRNA, Microbial technologies and Bioscience products

The Capsules & Health Ingredients business continues to operate in its existing structure.

Aligned to the One Lonza organizational structure, the updated financials for 2024 provide investors with comparable figures for the Half-Year 2025 reporting, which will be published on 23 July 2025, and the Full-Year 2025 reporting.

The 2024 Comparative Financials Report can be viewed here.